These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 24498016

  • 1. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.
    PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [Abstract] [Full Text] [Related]

  • 3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR.
    J Transl Med; 2019 Oct 03; 17(1):334. PubMed ID: 31581940
    [Abstract] [Full Text] [Related]

  • 4. Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.
    McDermott AM, Kerin MJ, Miller N.
    PLoS One; 2013 Oct 03; 8(12):e83718. PubMed ID: 24391813
    [Abstract] [Full Text] [Related]

  • 5. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY, Jia S, Zhang WH, Zhang Y, Kang Y, Li PS.
    Asian Pac J Cancer Prev; 2013 Oct 03; 14(5):3197-203. PubMed ID: 23803104
    [Abstract] [Full Text] [Related]

  • 6. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.
    Endocr Relat Cancer; 2013 Feb 03; 20(1):91-102. PubMed ID: 23183268
    [Abstract] [Full Text] [Related]

  • 7. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
    Kalinina T, Kononchuk V, Alekseenok E, Obukhova D, Sidorov S, Strunkin D, Gulyaeva L.
    Genes (Basel); 2021 Apr 16; 12(4):. PubMed ID: 33923732
    [Abstract] [Full Text] [Related]

  • 8. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY, Wang B, Li YH, Chen X, Wang YW, Liu HT, Gao P.
    Pathol Oncol Res; 2021 Apr 16; 27():1609753. PubMed ID: 34257614
    [Abstract] [Full Text] [Related]

  • 9. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E.
    Breast Cancer Res; 2020 Jun 30; 22(1):73. PubMed ID: 32605588
    [Abstract] [Full Text] [Related]

  • 10. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF, Oliveira RJ, O Silva VA, D C Vieira RA, Reis RM, C Marques MM.
    BMC Cancer; 2021 Jan 18; 21(1):76. PubMed ID: 33461524
    [Abstract] [Full Text] [Related]

  • 11. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, Brown JAL, Kerin MJ.
    BMC Cancer; 2019 May 10; 19(1):436. PubMed ID: 31077182
    [Abstract] [Full Text] [Related]

  • 12. Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer- A Comparison.
    Arabkari V, Clancy E, Dwyer RM, Kerin MJ, Kalinina O, Holian E, Newell J, Smith TJ.
    Pathol Oncol Res; 2020 Apr 10; 26(2):833-844. PubMed ID: 30840191
    [Abstract] [Full Text] [Related]

  • 13. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
    Nassar FJ, El Sabban M, Zgheib NK, Tfayli A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A, Calin GA, Nasr R.
    PLoS One; 2014 Apr 10; 9(9):e107566. PubMed ID: 25232827
    [Abstract] [Full Text] [Related]

  • 14. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
    Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.
    Mol Oncol; 2014 Jul 10; 8(5):874-83. PubMed ID: 24694649
    [Abstract] [Full Text] [Related]

  • 15. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen.
    McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M.
    J Biol Chem; 2018 Jan 26; 293(4):1163-1177. PubMed ID: 29162724
    [Abstract] [Full Text] [Related]

  • 16. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B, Li J, Sun M, Sun L, Zhang X.
    IUBMB Life; 2014 May 26; 66(5):371-7. PubMed ID: 24846313
    [Abstract] [Full Text] [Related]

  • 17. Differential microRNA expression in breast cancer with different onset age.
    Tsai HP, Huang SF, Li CF, Chien HT, Chen SC.
    PLoS One; 2018 May 26; 13(1):e0191195. PubMed ID: 29324832
    [Abstract] [Full Text] [Related]

  • 18. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
    Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC, Ma R.
    Gene; 2017 Jul 01; 619():10-20. PubMed ID: 28359916
    [Abstract] [Full Text] [Related]

  • 19. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer.
    Zhang K, Wang YY, Xu Y, Zhang L, Zhu J, Si PC, Wang YW, Ma R.
    Pathol Res Pract; 2021 Jun 01; 222():153458. PubMed ID: 33962174
    [Abstract] [Full Text] [Related]

  • 20. Circulating microRNA-based screening tool for breast cancer.
    Frères P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H, Kridelka F, Lifrange E, Jossa V, Bours V, Josse C, Jerusalem G.
    Oncotarget; 2016 Feb 02; 7(5):5416-28. PubMed ID: 26734993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.